Received Date : 21-Dec-2015

Revised Date : 12-Apr-2016

Accepted Date : 24-Apr-2016

Article type : Radiation Oncology Original Article

Title: Lung Cancer Radiation therapy in Australia and New Zealand:
patterns of practice

Running Head: Lung radiation therapy patterns of practice: Australia and New Zealand

Authors:

Dr. Syed Muntasser Islam¹

Dr. Shalini K Vinod²

Dr. Margot Lehman³

Dr. Shankar Siva⁴

Prof. Tomas Kron⁵

Dr. Patrick M Dwyer⁶

Dr. Lois Holloway⁷⁻⁹

Dr. Louis Lao¹⁰⁻¹²

Dr. Mei-Ling Yap^{9,13-14}

Dr. Jeremy D Ruben^{1,15}

1. Radiation Oncology, William Buckland Radiotherapy Centre, Melbourne, Victoria, Australia
2. Cancer Therapy Centre, Liverpool Hospital, Liverpool BC, New South Wales, Australia
3. Radiation Oncology, Princess Alexandra Hospital, Brisbane, Queensland, Australia

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/1754-9485.12475](https://doi.org/10.1111/1754-9485.12475)

This article is protected by copyright. All rights reserved

4. Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
5. Medical Physics, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
6. North Coast Cancer Institute, Lismore, New South Wales, Australia
7. Medical Physics, Liverpool Hospital, Liverpool BC, New South Wales, Australia
8. South Western Clinical School, University of New South Wales
9. Ingham Institute for Applied Medical Research, Liverpool BC, New South Wales, Australia
10. Radiation Oncology, Auckland City Hospital, Auckland, New Zealand
11. Auckland Radiation Oncology, Auckland, New Zealand
12. University of Auckland, Auckland, New Zealand
13. Radiation Oncology, Liverpool Hospital, Liverpool BC, New South Wales, Australia
14. Radiation Oncology, Macarthur Cancer Therapy Centre, Western Sydney University, Campbelltown, New South Wales, Australia
15. Monash University, Melbourne, Victoria, Australia

Corresponding Author:

Dr. Syed Muntasser Islam

William Buckland Radiotherapy Centre

The Alfred

Commercial Rd

Prahran, 3181

Victoria, Australia

Phone: 03 9076 2000

Fax: 03 9076 2916

Mobile: 04 3333 1985

Email: muntasser@gmail.com

Abstract

Introduction: The RANZCR Faculty of Radiation Oncology Lung Interest Cooperative (FROLIC) surveyed patterns of lung cancer radiation therapy practice for non-small cell (NSCLC) and small cell lung cancer (SCLC) to evaluate current patterns of care and potential for improvement.

Methods: In October 2014 Radiation Oncologists (ROs) from all 62 departments in Australia and New Zealand were invited to a web-based survey directed at those treating lung cancer. Questions covered current radiation therapy practice as well as quality measures.

Results: Fifty-eight percent of respondents used 4D-CT simulation. For curative treatment, 98% employed 3D-CRT and 34% intensity modulated radiotherapy (IMRT) techniques. Treatment verification was primarily performed using cone-beam CT (86%). In NSCLC, the commonest curative dose-fractionation regime was 60Gy/30# (96%) and for palliative intent, 30Gy/10# (76%). Forty-four percent treated patients with stereotactic ablative body radiotherapy (SABR) and half treated central tumours with this technique. In fit patients with synchronous solitary brain metastases, 80% would give radical treatment. For curative-intent SCLC, 45-50.4Gy/25-28# (61%) and 45Gy/30#/1.5Gy b.d. (48%) were used. Ninety-four percent discussed lung cancer patients at multidisciplinary meetings. Contours were peer-reviewed by 74% and 50% for conventional fractionation and SABR, respectively.

Conclusion: A significant proportion of ROs did not have access to 4D-CT. The majority used 3D image verification and consistently prescribed evidence based doses. A significant number did not participate in peer-review of contours. Practice in IMRT and synchronous oligo-metastatic disease is variable and should be an area of future research. Utilising survey findings, FROLIC is developing consensus recommendations to guide practice.

Keywords: Patterns of Practice, lung cancer, SABR, oligo-metastatic, IMRT, 4D-CT

1 Introduction

- 2 Radiation therapy plays an important role in the management of all stages of lung cancer for both cure and
3 palliation¹. Despite advances in chemotherapy, surgery and radiation therapy technique, improvements in

overall survival have been modest. From 1982–1986 to 2007–2011, 5-year relative survival for lung cancer has only improved from 8% to 14%². Lung cancer remains the leading cause of cancer related morbidity and mortality in the Australian population². Despite lung cancer's prevalence and associated mortality rate, prior studies show significant variability in practice³⁻⁴, not only on a national basis, but also within the same state or province.

Detailed surveys specific to Australia and New Zealand lung radiation therapy practice were last conducted in 2007⁵. Since then, technologies in lung cancer radiation therapy have continued to evolve, and there has been increasing adoption of 4-dimensional computed tomography (4D-CT) for tumour motion management and advanced treatment techniques such as Stereotactic Ablative Body Radiotherapy (SABR) and Intensity-modulated radiation therapy (IMRT).

The aim of this study is to evaluate current patterns of care with respect to radiation therapy management of lung cancer throughout Australia and New Zealand in order to highlight areas for future research and quality improvement.

Methods

In October 2014 a web based survey designed using the SurveyMonkey® software was developed to understand how Radiation Oncologists (ROs) (both subspecialists and generalists) in Australia and New Zealand manage lung cancer.

To reach the widest possible audience, ROs in all 62 departments from Australia and New Zealand were emailed utilising the RANZCR database, with replies obtained from all states and territories. This data is to date the most complete representation yet of practice in Australia and New Zealand.

There were a total of 36 questions, reviewed by lung cancer subspecialist ROs at the inaugural RANZCR Faculty of Radiation Oncology Lung Interest Cooperative (FROLIC) meeting in September 2014. Questions were designed to obtain information on demographics, simulation techniques, treatment planning, motion management, quality assurance measures, SABR practice, management of oligometastatic disease and small cell lung cancer treatment. The survey was intentionally structured in order to keep average completion time to within 15 minutes, thereby reducing "survey fatigue" whilst maintaining an acceptable completion rate. Question logic software was used to target only ROs who treated lung cancer, and again later in the survey to direct only those who used SABR to an additional set of questions and scenarios relating to SABR.

To protect participant privacy, no department information was collected; however demographic information on State/Territory of practice, rural vs metropolitan and whether the RO was a subspecialist in lung cancer was collected. A subspecialist in lung cancer was defined by FROLIC as any RO with a special interest in treating lung cancer or for whom treating thoracic malignancies constitutes the majority of their practice.

Ethics approval was not required for the study. Responses were collected from 24th October 2014 to 17th November 2014. A descriptive analysis was performed with the results presented as a percentage of evaluable

responses. If the survey was partially completed, a response was considered evaluable if the question was completed.

Results

Sixty-two responses were received, representing 16% of all Australian and New Zealand ROs registered with the Royal Australian and New Zealand College of Radiologists (RANZCR). Of these, 57 (92%) respondents treated patients with lung cancer and were eligible for analysis.

Forty-five of 57 respondents (79%) answered all questions in the survey. Sixty-one percent of respondents were from metropolitan centres and 39% from regional centres. The demographics of respondents by State/Territory is shown in Fig. 1.

Sixty percent of respondents indicated they were subspecialists in lung cancer. Respondents individually saw a mean of 57 and median of 40 (range 5-200) new lung cancer patients per year. Subspecialists saw a mean of 74 (range 15 – 200) as compared to 30 (range 5-75) for non-subspecialists.

Participation in Trials

Sixty percent of respondents reported they were participating in a lung cancer clinical trial (not specific to radiation therapy). Of the 23 respondents not participating in clinical trials, the key reasons cited were lack of radiation specific trials (38%) lack of trial support staff/infrastructure (25%) or not being equipped for SABR (19%). Nineteen percent of respondents said their research unit was still being set up at the time. Only one respondent (6%) cited lack of funding as a barrier to participation in clinical trials.

Simulation and planning in non-small cell lung cancer

Tumour Motion Management: Radical Intent

ROs were asked to select all options they used in practice for motion management. Fifty-eight percent of respondents used 4D-CT, while 35% used free breathing CT. Positron emission tomography-computed tomography (PET-CT) was commonly used with 23% using PET-CT simulation and 44% PET-CT-fusion. Thirteen percent used gated CT for planning and 12% used peak inspiration and expiration scans. Fluoroscopy was rarely used (2%). One respondent used PET fusion and performed three simulation CT scans, planning treatment using the CT which showed the best correlation of the GTV to the PET scan.

Tumour Motion Management: Palliative Intent

For palliative patients, ROs were asked to select all options they would use for motion management. The vast majority of ROs used free breathing CT (81%). 23% used PET fusion if available and 23% used the same scans as for curative patients.

68

69 *Respiratory Gating Techniques*

70 Most ROs did not routinely use respiratory gating. Fifty-six percent of respondents had never utilised breath
71 hold or respiratory gating during simulation. Of the 44% who had used it during simulation, 21% regularly used
72 respiratory gating and 9% breath hold. One respondent (2%) used both techniques for all patients.

73

74 *Dose Calculation Algorithms*

75 *Curative*

76 Monte Carlo (35%) was the most common dose calculation algorithm used in curative treatments, followed by
77 Anisotropic Analytical Algorithm (Varian Medical Systems, Palo Alto, CA) (27%) and other point kernel dose
78 algorithms (25%) i.e. collapsed cone convolution, CMS XIO (Computerized Medical Systems, USA), Raystation
79 (RaySearch Laboratories, Stockholm, Sweden), convolution and superposition/convolution. Less common
80 responses included "Type B algorithms" which take into account lateral electron dose equilibrium (and would
81 include all the algorithms specified above even if the specific algorithm was not specified).

82 *Palliative*

83 In palliative treatments, respondents largely used the same dose calculation algorithms as selected for curative
84 treatments. However, Monte Carlo was employed less often (25%), so that AAA (27%) and other point kernel
85 techniques (29%) predominated.

86 *Treatment*

87 *Treatment Techniques: Curative Intent*

88 ROs were asked what techniques they used to treat patients with curative intent; and allowed to select any
89 that applied. 3D-CRT was used by 98%, with 34% having used IMRT and 18% VMAT. Despite one centre having
90 Cyberknife® available, no respondents reported using this for lung treatment. Two respondents (4%) noted
91 treating patients using helical tomotherapy.

92 *Treatment Verification*

93 ROs were asked which treatment verification techniques they used for curative treatment. The majority
94 utilised 3D cone beam CT (86%) and KV imaging (72%). Thirty percent used MV imaging, 12% used 4D cone
95 beam CT and 6% of respondents used ExacTrac®.

96 In terms of imaging frequency, 52 % of respondents used daily CBCT (3D or 4D) during treatment. Thirty two
97 percent used a daily CBCT initially on Days 1 to 3-6 then weekly. Only 6% would use daily KV with a weekly
98 CBCT and 4% of respondents would use a 4D-CBCT on day one and then daily CBCT. The remaining 6% stated
99 that their practice varies.

Implanted Fiducial Markers

No respondents used fiducials during conventional radiation therapy, while 10% would use fiducials during SABR only.

Lung SABR

Forty-four percent of respondents surveyed were treating patients with lung SABR. Respondents were treating a mean of 8 patients (range 0-20) cases per year.

Immobilisation during SABR

ROs were asked how they immobilised patients during SABR and allowed to select all options that applied. Sixty-five percent used a vacuum bag/vac-fix cushion. Fifty percent also used a dedicated commercial product. Five percent reported using abdominal compression.

Treatment Verification during SABR

ROs were asked to select all treatment verification options they employed for SABR. Seventy-five percent used 3D-CBCT and 50% used 4D-CBCT. A smaller number used KV imaging (25%) or Exactrac (15%). All respondents stated that they performed image verification for every SABR fraction, and 60% performed pre, mid and post fraction verification.

Peripheral tumours not close to chest wall

ROs were asked to select all dose / fractionation schedules they used for peripheral tumours not close to the chest wall. The most common schedule was 54Gy/3#, employed by 80% of respondents. 30% used 48Gy/4#. The other fractionation schedule used by one respondent was 54Gy/4#.

Peripheral tumours close to the chest wall

With tumours close to the chest wall, 70% responded that they would use 48Gy/4#, whilst 20% would use 55Gy/5# and 10% would not treat lesions close to the chest wall.

Central Tumours

There was significant heterogeneity in practice for central lesions. Fifty percent of respondents would not treat central lesions. Thirty percent would use 60Gy in 8# and 15% prefer 50Gy/5#. One respondent used 18Gy/1# to treat a central lesion. Three respondents wrote that they would only treat the central zone in specific scenarios (avoiding very central/hilar tumours, or only treating on trial).

Conventional Treatment

For conventional curative intent treatment in node positive and node negative NSCLC, dose / fractionation schedules that were employed are shown in Fig. 2 and 3 respectively. Respondents were allowed to choose more than one schedule. In both cases, "Other" responses used doses between 64Gy/32# and 65Gy/35#, while one respondent chose 70Gy/35# in both scenarios.

Large volume disease precluding radical intent radiation therapy

Significant variation in practice was observed in this area. Schedules employed are outlined in Fig. 4. Respondents were allowed to choose more than one schedule. "Other" schedules in use by 22% included 16-17Gy/2#, 36.5Gy/15#, 45Gy/15#, 45Gy/25#, 54Gy/30#, 50Gy/20# and one respondent responded that they would use an "isotoxic regimen".

Oligo-metastatic disease

The survey results show large variations in practice when offering radical treatment to oligo-metastatic sites. We assessed willingness to offer radical treatment using a series of scenarios involving a fit patient of good performance status who had received definitive treatment of the primary tumour.

Brain Metastases

Fig. 5. shows the percentage of respondents willing to treat with radical intent in the setting of a solitary brain metastasis or up to three brain metastases. Respondents were allowed to choose more than one answer.

Systemic Oligo-metastases

For patients with systemic oligo-metastases (eg: adrenal, bone, liver) 35% stated they would offer radical intent treatment to both chest and extrathoracic disease if there was a single systemic metastasis. This reduced markedly to 6.5% for two metastases and 2% for both three to five or fewer metastases. Sixty-one percent stated they do not offer definitive treatment in the setting of systemic oligo-metastases.

Small Cell Lung Cancer

Limited Stage: Curative Intent Fractionation Schedules

Dose / fractionation schedules employed in limited stage SCLC are shown in Fig. 6. Respondents were allowed to choose more than one schedule.

Extensive Stage: Consolidation Chest RT

Sixty-three percent of ROs stated they would give consolidation chest RT for patients who achieved a complete response to chemotherapy at metastatic sites, 48% if a partial response was achieved at metastatic sites and 24% would not routinely give consolidation chest RT in ES-SCLC. Respondents were allowed to choose more than one option for this scenario.

Quality Assurance Practices

Discussion of new patients at MDT

Ninety four percent of respondents discussed new lung cancer patients at a multidisciplinary team meeting. Of these, 63% responded that they would refer all new lung cases to an MDT, 11% would refer curative cases only and 20% would refer only selected patients. Specific criteria used by ROs to “select” patients was not further elucidated by the survey.

Peer Review Meetings

Seventy-four percent of respondents stated that they have a peer review meeting to evaluate lung contours for conventional fractionation in both curative and palliative patients. Most commonly (44%), these meetings were to discuss selected patients (either with curative or palliative intent). For SABR cases, 50% of respondents had a peer review meeting to discuss contours for patients with both curative and palliative intent.

Department Protocols

Only 37% of departments had both a dose and contouring protocol for lung cancer. Thirty-nine percent relied on external protocols eg: EviQ⁶. Eleven percent did not have a protocol for contouring or dose prescription.

Discussion

To our knowledge this is the first patterns of practice survey to evaluate the use of new technologies, quality assurance activities, clinical trial participation and management of oligo-metastases in the context of lung cancer. A North American survey of ASTRO members was conducted in 2014⁷, however this did not address oligo-metastatic disease or quality control activities, eg: multi-disciplinary tumour board (MDT) participation, contouring guidelines and peer-review.

The survey was sent to every Radiation Oncology department in Australia and New Zealand and drew responses from 16% of all ROs. This is a similar response rate to the ASTRO study (20%)⁷. However as respondents were not asked to identify their centre, there may be disproportionately more responses from certain centres.

If considering responders from Australia only; 33%, 29% and 21% were from Victoria, NSW and QLD respectively. Comparison using Medicare data⁸ of geographic distribution of the Australian Radiation Oncology Workforce for the same states was 30%, 34% and 18% respectively. This suggests responses were fairly distributed by State/Territory.

The survey shows that most practitioners follow evidence based practice where evidence exists. This may be affected by resource or patient factors for example in SCLC, where many chose 40Gy/15# once daily rather than a b.d. regimen and in node negative locally advanced NSCLC where many use hypofractionation. It is likely that hypofractionated regimens are used in those of poorer performance status but the question was not

detailed enough to elucidate this with certainty. In keeping with results of RTOG 0617¹⁰, dose escalation beyond 60Gy for locally advanced NSCLC was uncommon.

The use of respiratory gating was uncommon and when used, was usually for selected patients only. This reflects uncertainty around the potential benefits of gating, its resource demands and the complexity of its execution¹¹. A significant percentage of ROs (42%) did not have access to 4D-CT. In this subgroup, the majority used PET/CT to account for tumour motion. Current Australian lung cancer guidelines recommend either 4D-CT or PET to assess tumour motion¹. The survey also demonstrates significant uptake of newer radiation therapy techniques such as IMRT (34%) and VMAT (18%) amongst Australia and New Zealand ROs despite the paucity of high-level clinical evidence demonstrating its benefit over 3D-CRT. The current evidence for IMRT in the setting of lung cancer is limited to those retrospective in nature. However a retrospective review from MD Anderson Cancer Centre showed 4DCRT/IMRT resulted in a significant reduction in toxicity (particularly freedom from Grade3 radiation pneumonitis) and a significant improvement in overall survival (OS) compared with CT/3D-CRT¹². As the 3D-CRT arm did not use 4D-CT planning, it is unclear what proportion of this benefit was due to use of the IMRT technique. Conversely, the SEER comparative effectiveness study showed no difference in survival between 3D conformal and IMRT, and no difference in toxicities¹³. These current uncertainties in the evidence have lead to a recent article¹⁴ highlighting the need for prospective comparative studies. When questioned about current gaps in evidence, the survey demonstrated significant interest in evaluating the clinical benefit of IMRT vs 3D-CRT in a trial setting.

SABR for early stage lung cancer is widely practised (44%), and there is general consensus on dose for peripheral tumours far from the chest wall (54Gy/3# in 80%) and those close to the chest wall (48Gy/4# in 70%). The variety of dose schedules for central tumours reflects the paucity of high level data and variation in published studies. The results of the CHISEL trial¹⁵ are still awaited. The treatment of central tumours is a controversial area. Just half of SABR practitioners were treating central tumours; generally using a risk adapted approach and published regimens¹⁶.

The commonest curative regimen for node positive NSCLC was 60Gy in 30 fractions although 30% also used 66Gy in 33 fractions. This practice is concordant with results of published studies¹⁷. Only a single respondent had used 70Gy. For node negative patients with NSCLC, respondents tended to use hypofractionated doses more frequently than for node positive disease. This finding is probably due to smaller and more peripheral planned target volumes (PTV) in node negative disease. Conversely for palliative patients, the wide range of doses employed reflect variables such as performance status and limitations of lung DVHs. A wide range of schedules was used (most commonly 30Gy/10# by 76% and 36Gy/12# by 72%). Thirteen percent of ROs stated they would also treat to higher doses using an isotoxic dose regimen. The survey demonstrates that the use of higher doses to improve local control and survival in better performance status patients is recognised by Australia and New Zealand ROs even when curative intent treatment cannot be given. Most participants nominated more than one potential dose/fractionation regime for the same clinical scenario, reflecting the practice of using “personalised medicine” to tailor the dose based on patient fitness/OAR constraints etc.

Alternatively this could reflect inconsistency in dose prescription or ROs practicing at more than one site with a differing suite of technologies available at each location. This was not further elucidated by the survey

Eighty percent of ROs were likely to offer radical intent treatment for a fit patient with solitary brain metastasis and no extrathoracic disease. This is consistent with findings from Flannery et al¹⁸ which showed that median overall survival (OS) for a synchronous solitary brain metastases from NSCLC treated with stereotactic radiosurgery (SRS) was 18 months. A randomized trial (RTOG 95-08¹⁹) also suggests a functional autonomy benefit to WBRT + SRS, and survival benefit for 1 metastasis.

In the presence of up to three brain metastases, 46% of ROs would consider treating the brain definitively. The heterogeneity in answers most likely reflects the absence of high level evidence to show a survival benefit in treating three brain metastases. A recent meta-analysis²⁰ does suggest a survival benefit in patients aged <50 with 1-4 brain metastases, although patients with a single metastasis had significantly better survival than those who had 2-4 metastases. Studies in these patients, to date, have however demonstrated that the addition of a SRS boost to WBRT improves local control and functional autonomy and reduces steroid use¹⁹. Some participants who replied in favour of SRS may have also been influenced by recent randomised evidence demonstrating the negative effect of WBRT on quality of life and cognition²¹⁻²², thus preferring radiosurgery.

In contrast to oligometastatic brain disease, the paucity of data for systemic oligometastases is reflected in the low numbers of clinicians who would approach such patients with definitive radiation therapy, especially if multiple oligometastases are present. Active trials are underway such as SABR COMET²³ and SAFRON II²⁴ that will hopefully provide data in this area.

In the setting of extensive stage small cell lung cancer, 24% of ROs did not routinely give consolidation chest radiation therapy. This survey closed prior to publication of the CREST trial²⁵ (published January 2015) which demonstrated a non-significant hazard ratio for survival although a survival advantage at 2 years (13% vs 3%) and improved progression free survival at 6 months (24% vs 7%) with no severe toxic effects. It will be interesting to see the effect this trial has on future practice.

The vast majority of ROs (94%) discuss lung cancer patients at a MDT meeting. Numerous studies show discussing patients at an MDT meeting reduces diagnostic and treatment delays²⁶⁻²⁷ and significantly impact on the management plans in 58% of lung cancer patients. There is also evidence that discussion at MDT meeting may also be associated with improved survival²⁸.

Seventy four percent of ROs would discuss conventional fractionation lung contours at a peer review meeting and 50% for SABR. A retrospective study of lung SABR plans recommended minor or major changes in up to two thirds of contoured structures, suggesting peer review resulted in significant changes in lung SABR plans and is warranted to improve consistency and quality of planning²⁹.

Conclusion

This survey shows the majority of Australia and New Zealand ROs consistently prescribed evidence based doses and used 3D image verification. A significant proportion of ROs did not have access to 4DCT for simulation. Although protocols were widely used, not every department has their own protocol. There is a need to publish standardised management protocols to guide Australia and New Zealand practice. Almost all patients were discussed at a lung MDT meeting, however a significant number of ROs did not participate in peer review of contours. There is a need to encourage peer review activity. The use of IMRT vs 3D-CRT, the treatment of synchronous oligometastatic disease were variable, likely due to a lack of high quality evidence and should be an area of future research. As a result of findings from this survey, FROLIC is developing consensus recommendations on best practice radiation therapy to complement existing national guidelines¹.

Acknowledgements:

I would like to gratefully acknowledge the time and contribution of the survey respondents and all members of the Faculty of Radiation Oncology Lung Interest Committee (FROLIC) for their input into this survey.

References

1. Cancer Council Australia Lung Cancer Guidelines Working Party. Clinical practice guidelines for the treatment of lung cancer. [<http://wiki.cancer.org.au/australiawiki/index.php?oldid=99968>] Sydney: Cancer Council Australia, [Updated 28 January 2015, cited 2015 Sep 27]. Available from: http://wiki.cancer.org.au/australia/Guidelines:Lung_cancer.
2. Australian Institute of Health and Welfare & Australasian Association of Cancer Registries 2010. Cancer in Australia: an overview, 2010. Cancer series no. 60. Cat. no. CAN 56. Canberra: AIHW.
3. Barbera L, Zhang-Salomons J, Huang J, Tyldesley S, Mackillop W. Defining the Need for Radiotherapy for Lung Cancer in the General Population. *Medical Care*. 2003;41(9):1074-1085.
4. Denham J. How do we bring an acceptable level of radiotherapy services to a dispersed population?. *Australasian Radiology*. 1995;39(2):171-173.
5. Holloway, L. Current practice when treating lung cancer in Australasia. *Australasian Radiology*. 2007;51(1):62-67.
6. eviQ Cancer Treatments Online 2015. [<https://www.eviq.org.au>] Cancer Institute NSW, [Updated November 2015, cited 2015 November 29]. Available from: <https://www.eviq.org.au/>
7. Kong F, Cuneo K, Wang L, Bonner J, Gaspar L, Komaki R et al. Patterns of practice in radiation therapy for non-small cell lung cancer among members of the American Society for Radiation Oncology. *Practical Radiation Oncology*. 2014;4(2):e133-e141.

8. Australian Medical Workforce Advisory Committee (1998), The Specialist Radiation Oncology Workforce In Australia, AMWAC Report 1998.2, Sydney
9. Murray N, Zee B, Pater J, Coy P, Hodson I, Arnold A et al. Importance of timing for thoracic irradiation (TI) in the combined modality treatment of limited-stage small-cell lung cancer (LSCLC): An update of the National Cancer Institute of Canada (NCIC) BR6 study. *Lung Cancer*. 1997;18:61.
10. Bradley J, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. *The Lancet Oncology*. 2015;16(2):187-199.
11. Ruben JD. Respiratory-gated thoracic radiotherapy: much complexity for how much gain? *Journal of Medical Imaging and Radiation Oncology*. 2013 Dec;57(6):701–3.
12. Liao Z, Komaki R, Thames H, Liu H, Tucker S, Mohan R et al. Influence of Technologic Advances on Outcomes in Patients With Unresectable, Locally Advanced Non–Small-Cell Lung Cancer Receiving Concomitant Chemoradiotherapy. *International Journal of Radiation Oncology*Biophysics*. 2010;76(3):775-781.
13. Harris JP, Murphy JD, Hanlon AL, Le QT, Loo BW, Jr., Diehn M. A population-based comparative effectiveness study of radiation therapy techniques in stage III non-small cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2014;88(4):872-84.
14. Price A. Intensity-modulated radiotherapy, not 3 dimensional conformal, is the preferred technique for treating locally advanced disease with high-dose radiotherapy: the argument against. *Semin Radiat Oncol*. 2015;25(2):117-21.
15. TROG 09.02 (CHISEL). [<http://www.trog.com.au/TROG-0902-CHISEL>] Ball D; 2015 [cited 2015 Nov 29]. Available from: <http://www.trog.com.au/TROG-0902-CHISEL>.
16. Brock J, Ashley S, Bedford J, Nioutsikou E, Partridge M, Brada M. [Review of hypofractionated small volume radiotherapy for early-stage non-small cell lung cancer](#). *Clin Oncol (R Coll Radiol)* 2008 Nov;20(9):666-76
17. Non-small Cell Lung Cancer Collaborative Group. [Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials](#). *BMJ* 1995;311(7010):899-909
18. Flannery TW, Suntharalingam M, Regine WF, Chin LS, Krasna MJ, Shehata MK, Edelman MJ, Kremer M, Patchell RA, Kwok Y. Long-term survival in patients with synchronous, solitary brain metastasis from non–small-cell lung cancer treated with radiosurgery. *Int J Radiat Oncol Biol Phys*. 2008;72:19-23.
19. Andrews D, Scott C, Sperduto P, Flanders A, Gaspar L, Schell M et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. *The Lancet*. 2004;363(9422):1665-1672.
20. Sahgal A1, Aoyama H2, Kocher M3, Neupane B4, Collette S5, Tago M6, Shaw P7, Beyene J4, Chang EL8, Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to

4 brain metastases: individual patient data meta-analysis, *Int J Radiat Oncol Biol Phys*. 2015 Mar 15;91(4):710-7. doi: 10.1016/j.ijrobp.2014.10.024.

21. Soffietti R, Kocher M, Abacioglu U, Villa S, Fauchon F, Baumert B et al. A European Organisation for Research and Treatment of Cancer Phase III Trial of Adjuvant Whole-Brain Radiotherapy Versus Observation in Patients With One to Three Brain Metastases From Solid Tumors After Surgical Resection or Radiosurgery: Quality-of-Life Results. *Journal of Clinical Oncology*. 2012;31(1):65-72.
22. Chang E, Wefel J, Hess K, Allen P, Lang F, Kornguth D et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. *The Lancet Oncology*. 2009;10(11):1037-1044.
23. Palma DA, Haasbeek CJA, Rodrigues GB, et al. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial. *BMC Cancer*. 2012;12:305. doi:10.1186/1471-2407-12-305.
24. Siva, Shankar, Tomas Kron, Mathias Bressel, Marion Haas, Tao Mai, Shalini Vinod, Giuseppe Sasso et al. "A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II)." *BMC cancer* 16, no. 1 (2016): 1.
25. Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. *Lancet* 2015;385:36-42.
26. Ung K, Campbell B, Duplan D, Ball D, David S. Impact of the lung oncology multidisciplinary team meetings on the management of patients with cancer. *Asia-Pacific Journal of Clinical Oncology*. 2014;;n/a-n/a.
27. Salomaa ER, [Sällinen S](#), [Hiekkanen H](#), [Liippo K](#) et al. Delays in the diagnosis and treatment of lung cancer. [Chest](#). 2005 Oct;128(4):2282-8.
28. Mitchell PL, Thursfield VJ, Ball DL, Richardson GE, Irving LB, Torn-Broers Y, et al. Lung cancer in Victoria: are we making progress? *Med J Aust*. 2013;199(10):674-9
29. Lo A, Liu M, Chan E, Lund C, Truong P, Loewen S et al. The Impact of Peer Review of Volume Delineation in Stereotactic Body Radiation Therapy Planning for Primary Lung Cancer. *Journal of Thoracic Oncology*. 2014;9(4):527-533.

Figure Legends:

Fig. 1. Demographics of Respondents by State/Territory

Fig. 2. Dose / fractionation schedules used by ROs for curative node positive NSCLC

Fig. 3. Dose / fractionation schedules used by ROs for curative node negative NSCLC

Fig. 4. Dose / fractionation schedules used by ROs for large volume NSCLC precluding curative radiation therapy

Fig. 5. Percentage of ROs willing to treat a fit patient of good performance status with a solitary brain metastasis or up to three brain metastases with radical intent if receiving definitive treatment to the primary

Fig. 6. Dose / fractionation schedules used by ROs for limited stage SCLC

Figures:

Uploaded separately in individual word documents. Figures created using Microsoft Excel. They have not been submitted as pictures as this would degrade the quality when rescaling.

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Islam, SM;Vinod, SK;Lehman, M;Siva, S;Kron, T;Dwyer, PM;Holloway, L;Lao, L;Yap, ML;Ruben, JD

Title:

Lung cancer radiation therapy in Australia and New Zealand: Patterns of practice

Date:

2016-10-01

Citation:

Islam, S. M., Vinod, S. K., Lehman, M., Siva, S., Kron, T., Dwyer, P. M., Holloway, L., Lao, L., Yap, M. L. & Ruben, J. D. (2016). Lung cancer radiation therapy in Australia and New Zealand: Patterns of practice. JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 60 (5), pp.677-685. <https://doi.org/10.1111/1754-9485.12475>.

Persistent Link:

<http://hdl.handle.net/11343/291403>